Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LGMN | Q99538 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158883 | 0.88 | LPL (0.41) | LPLLIPGKDM4EMAPTALDH1A1 | |
| SCHEMBL25717573 | 0.84 | KDM4E (0.35) | KDM4EPLAUMAPTALDH1A1RAB9A | |
| SCHEMBL29925545 | 0.83 | KDM4E (0.39) | KDM4EMAPTALDH1A1LGMNMEN1 | |
| SCHEMBL27032333 | 0.83 | KDM4E (0.39) | KDM4EMAPTALDH1A1LGMNMEN1 | |
| SCHEMBL27250467 | 0.82 | LPL (0.37) | LPLLIPG | |
| SCHEMBL3758967 | 0.82 | LPL (0.37) | LPLLIPG | |
| SCHEMBL30925342 | 0.82 | LPL (0.37) | LPLLIPG | |
| SCHEMBL17629331 | 0.82 | KDM4E (0.36) | KDM4EMAPTALDH1A1LGMNMEN1 | |
| SCHEMBL3753576 | 0.81 | LPL (0.36) | LPLLIPGALDH1A1MEN1KMT2A | |
| SCHEMBL21464790 | 0.81 | LPL (0.36) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622905-B2 | Aryl pladienolides for the treatment of neoplastic disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-05-12 | — | — | US | disclosed |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4543887-A2 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023250082-A2 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-117285502-A | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-112368270-B | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11679107-B2 | Certain aryl pladienolide compounds and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-06-20 | — | — | US | disclosed |
| EP-3039014-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | Lupin Atlantis Holdings SA (CH) | 2016-07-06 | — | — | EP | disclosed |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-08-20 | — | — | US | disclosed |
| US-9018205-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-28 | — | — | US | disclosed |
| WO-2015028938-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2015-03-05 | — | — | WO | disclosed |
| EP-2200436-B1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11679107-B2 | Certain aryl pladienolide compounds and methods of use | PLAAT5, PLAAT3, SNRPE | LPL 207/4885LIPG 457/4885KDM4E 1446/4885 |
| US-12622905-B2 | Aryl pladienolides for the treatment of neoplastic disorders | SF3B1, SF3B5, SF3B2 | LPL 335/4885LIPG 1158/4885KDM4E 3223/4885 |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | LPL 146/4885LIPG 618/4885KDM4E 1664/4885 |
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | LPL 4312/4885LIPG 1708/4885KDM4E 3764/4885 |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | LPL 4544/4885LIPG 4205/4885KDM4E 2345/4885 |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | LPL 4544/4885LIPG 4205/4885KDM4E 2345/4885 |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | LPL 4544/4885LIPG 4205/4885KDM4E 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.